Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia
Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S.
Frontiers17d
Artificial intelligence—based diagnosis of oral leukoplakia using deep convolutional neural networks Xception and MobileNet-v2
Materials and methods: Clinical photographs of oral leukoplakia and non-oral leukoplakia lesions were gathered from the SRM Dental College archives. An aggregate of 659 clinical photos, based on ...